JP2017528479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528479A5 JP2017528479A5 JP2017514346A JP2017514346A JP2017528479A5 JP 2017528479 A5 JP2017528479 A5 JP 2017528479A5 JP 2017514346 A JP2017514346 A JP 2017514346A JP 2017514346 A JP2017514346 A JP 2017514346A JP 2017528479 A5 JP2017528479 A5 JP 2017528479A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- concentration
- composition according
- rpl554
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000002245 particle Substances 0.000 claims 10
- -1 2,4,6-trimethylphenylimino Chemical group 0.000 claims 8
- CSOBIBXVIYAXFM-BYNJWEBRSA-N ensifentrine Chemical compound c-12cc(OC)c(OC)cc2CCn(c(n2CCNC(N)=O)=O)c-1c\c2=N/c1c(C)cc(C)cc1C CSOBIBXVIYAXFM-BYNJWEBRSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- PVKCAQKXTLCSBC-UHFFFAOYSA-N 1h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)C=NCC2=C1 PVKCAQKXTLCSBC-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012929 tonicity agent Substances 0.000 claims 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- OCAQSCOTLKDCIJ-UHFFFAOYSA-N C1CNC(N2C1=C1C=CC=CC1CC2)=O Chemical compound C1CNC(N2C1=C1C=CC=CC1CC2)=O OCAQSCOTLKDCIJ-UHFFFAOYSA-N 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 1
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1416274.7A GB201416274D0 (en) | 2014-09-15 | 2014-09-15 | Formulation |
| GB1416274.7 | 2014-09-15 | ||
| GB1504662.6 | 2015-03-19 | ||
| GBGB1504662.6A GB201504662D0 (en) | 2015-03-19 | 2015-03-19 | Formulation |
| PCT/GB2015/052668 WO2016042313A1 (en) | 2014-09-15 | 2015-09-15 | Liquid inhalation formulation comprising rpl554 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018238014A Division JP6795574B2 (ja) | 2014-09-15 | 2018-12-20 | Ｒｐｌ５５４を含む液体吸入製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528479A JP2017528479A (ja) | 2017-09-28 |
| JP2017528479A5 true JP2017528479A5 (enExample) | 2018-10-25 |
| JP6860477B2 JP6860477B2 (ja) | 2021-04-14 |
Family
ID=54196992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514346A Active JP6860477B2 (ja) | 2014-09-15 | 2015-09-15 | Ｒｐｌ５５４を含む液体吸入製剤 |
| JP2018238014A Active JP6795574B2 (ja) | 2014-09-15 | 2018-12-20 | Ｒｐｌ５５４を含む液体吸入製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018238014A Active JP6795574B2 (ja) | 2014-09-15 | 2018-12-20 | Ｒｐｌ５５４を含む液体吸入製剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9956171B2 (enExample) |
| EP (3) | EP3193835B1 (enExample) |
| JP (2) | JP6860477B2 (enExample) |
| KR (1) | KR102379309B1 (enExample) |
| CN (3) | CN110051627A (enExample) |
| AU (3) | AU2015316592B2 (enExample) |
| CA (1) | CA2959943C (enExample) |
| CY (3) | CY1120264T1 (enExample) |
| DK (3) | DK3193835T3 (enExample) |
| ES (3) | ES2875584T3 (enExample) |
| HK (1) | HK1249415B (enExample) |
| HR (3) | HRP20180833T1 (enExample) |
| HU (3) | HUE055527T2 (enExample) |
| IL (1) | IL250895B (enExample) |
| LT (3) | LT3332767T (enExample) |
| MX (1) | MX2017003102A (enExample) |
| MY (1) | MY196072A (enExample) |
| NO (1) | NO3193835T3 (enExample) |
| PH (1) | PH12017500479B1 (enExample) |
| PL (3) | PL3332767T3 (enExample) |
| PT (3) | PT3193835T (enExample) |
| RS (3) | RS57227B1 (enExample) |
| RU (1) | RU2699995C2 (enExample) |
| SG (1) | SG11201701854WA (enExample) |
| SI (3) | SI3332767T1 (enExample) |
| SM (3) | SMT201900340T1 (enExample) |
| WO (1) | WO2016042313A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10864213B2 (en) | 2014-05-12 | 2020-12-15 | Verona Pharma Plc | Treatment |
| MX2017003102A (es) * | 2014-09-15 | 2017-06-14 | Verona Pharma Plc | Formulacion para inhalacion liquida que comprende rpl554. |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| HK1251593A1 (zh) | 2015-07-24 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | Bace1抑制剂肽 |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| GB201911517D0 (en) | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| JP7712276B2 (ja) * | 2020-01-15 | 2025-07-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 三環式ｐｄｅ３／ｐｄｅ４二重阻害剤化合物の医薬組成物 |
| GB202002786D0 (en) * | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| JP2025527317A (ja) * | 2022-08-08 | 2025-08-20 | ヴェローナ ファーマ ピーエルシー | 中等度の慢性閉塞性肺疾患（ｃｏｐｄ）の治療のためのエンシフェントリン（ｒｐｌ－５５４） |
| JP2025528141A (ja) * | 2022-08-08 | 2025-08-26 | ヴェローナ ファーマ ピーエルシー | 液体医薬組成物 |
| KR20250087621A (ko) * | 2022-10-28 | 2025-06-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| US12194045B1 (en) | 2023-06-26 | 2025-01-14 | Verona Pharma Plc | Particulate composition |
| WO2025003643A1 (en) * | 2023-06-26 | 2025-01-02 | Verona Pharma Plc | Particulate composition comprising ensifetrine |
| WO2025052119A1 (en) * | 2023-09-06 | 2025-03-13 | Verona Pharma Plc | Ensifentrine for use in treating chronic obstructive pulmonary disease (copd) |
| US20250249006A1 (en) * | 2024-02-05 | 2025-08-07 | Verona Pharma Plc | Treatment |
| US20250249008A1 (en) * | 2024-02-07 | 2025-08-07 | Verona Pharma Plc | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease |
| US20250249007A1 (en) * | 2024-02-07 | 2025-08-07 | Verona Pharma Plc | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
| CA2305256C (en) | 1997-10-09 | 2005-05-17 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| ES2208310T3 (es) | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
| US6630169B1 (en) * | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0122031D0 (en) | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
| US7579505B2 (en) | 2004-12-17 | 2009-08-25 | Cipla Limited | Crystalline levosalbutamol sulphate and polymorphic forms thereof |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| CN102947300B (zh) * | 2010-06-22 | 2016-09-21 | 奇斯药制品公司 | 生物碱氨基酯衍生物及其药物组合物 |
| CA2807082C (en) | 2010-08-09 | 2017-07-25 | Verona Pharma Plc | Crystalline form of pyrimido[6,1-a]isoquinolin-4-one compound |
| CA2838529C (en) * | 2011-06-07 | 2020-03-24 | Parion Sciences, Inc. | Methods of treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| WO2014037727A1 (en) * | 2012-09-06 | 2014-03-13 | Verona Pharma Plc | Carcainium salts |
| JP6560986B2 (ja) | 2013-03-15 | 2019-08-14 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
| CN106105056B (zh) * | 2014-03-11 | 2019-07-12 | Lg电子株式会社 | D2d用户设备在通信系统中发送发现信号的方法和设备 |
| US10864213B2 (en) | 2014-05-12 | 2020-12-15 | Verona Pharma Plc | Treatment |
| MX2017003102A (es) * | 2014-09-15 | 2017-06-14 | Verona Pharma Plc | Formulacion para inhalacion liquida que comprende rpl554. |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2015
- 2015-09-15 MX MX2017003102A patent/MX2017003102A/es active IP Right Grant
- 2015-09-15 EP EP15770593.0A patent/EP3193835B1/en active Active
- 2015-09-15 SM SM20190340T patent/SMT201900340T1/it unknown
- 2015-09-15 HU HUE19152629A patent/HUE055527T2/hu unknown
- 2015-09-15 PT PT157705930T patent/PT3193835T/pt unknown
- 2015-09-15 AU AU2015316592A patent/AU2015316592B2/en active Active
- 2015-09-15 US US15/509,943 patent/US9956171B2/en active Active
- 2015-09-15 RS RS20180519A patent/RS57227B1/sr unknown
- 2015-09-15 ES ES19152629T patent/ES2875584T3/es active Active
- 2015-09-15 SI SI201530774T patent/SI3332767T1/sl unknown
- 2015-09-15 RS RS20211044A patent/RS62252B1/sr unknown
- 2015-09-15 CN CN201811561721.4A patent/CN110051627A/zh active Pending
- 2015-09-15 EP EP19152629.2A patent/EP3494962B1/en active Active
- 2015-09-15 ES ES15770593.0T patent/ES2670025T3/es active Active
- 2015-09-15 SM SM20180242T patent/SMT201800242T1/it unknown
- 2015-09-15 DK DK15770593.0T patent/DK3193835T3/en active
- 2015-09-15 HU HUE17207623A patent/HUE045303T2/hu unknown
- 2015-09-15 CN CN202010090019.5A patent/CN111249260B/zh active Active
- 2015-09-15 MY MYPI2017000391A patent/MY196072A/en unknown
- 2015-09-15 HR HRP20180833TT patent/HRP20180833T1/hr unknown
- 2015-09-15 JP JP2017514346A patent/JP6860477B2/ja active Active
- 2015-09-15 DK DK19152629.2T patent/DK3494962T3/da active
- 2015-09-15 SI SI201531657T patent/SI3494962T1/sl unknown
- 2015-09-15 PT PT191526292T patent/PT3494962T/pt unknown
- 2015-09-15 KR KR1020177006862A patent/KR102379309B1/ko active Active
- 2015-09-15 PT PT17207623T patent/PT3332767T/pt unknown
- 2015-09-15 LT LTEP17207623.4T patent/LT3332767T/lt unknown
- 2015-09-15 NO NO15770593A patent/NO3193835T3/no unknown
- 2015-09-15 RU RU2017108432A patent/RU2699995C2/ru active
- 2015-09-15 CA CA2959943A patent/CA2959943C/en active Active
- 2015-09-15 PL PL17207623T patent/PL3332767T3/pl unknown
- 2015-09-15 SG SG11201701854WA patent/SG11201701854WA/en unknown
- 2015-09-15 EP EP17207623.4A patent/EP3332767B1/en active Active
- 2015-09-15 LT LTEP19152629.2T patent/LT3494962T/lt unknown
- 2015-09-15 SI SI201530213T patent/SI3193835T1/en unknown
- 2015-09-15 PL PL19152629T patent/PL3494962T3/pl unknown
- 2015-09-15 DK DK17207623.4T patent/DK3332767T3/da active
- 2015-09-15 LT LTEP15770593.0T patent/LT3193835T/lt unknown
- 2015-09-15 HU HUE15770593A patent/HUE038433T2/hu unknown
- 2015-09-15 CN CN201580053062.1A patent/CN106794157B/zh active Active
- 2015-09-15 PL PL15770593T patent/PL3193835T3/pl unknown
- 2015-09-15 WO PCT/GB2015/052668 patent/WO2016042313A1/en not_active Ceased
- 2015-09-15 SM SM20210479T patent/SMT202100479T1/it unknown
- 2015-09-15 ES ES17207623T patent/ES2730810T3/es active Active
- 2015-09-15 RS RS20190765A patent/RS58897B1/sr unknown
-
2017
- 2017-03-02 IL IL250895A patent/IL250895B/en active IP Right Grant
- 2017-03-14 PH PH12017500479A patent/PH12017500479B1/en unknown
-
2018
- 2018-03-21 US US15/927,517 patent/US10945950B2/en active Active
- 2018-05-03 CY CY20181100455T patent/CY1120264T1/el unknown
- 2018-07-10 HK HK18108909.3A patent/HK1249415B/en unknown
- 2018-12-20 JP JP2018238014A patent/JP6795574B2/ja active Active
- 2018-12-24 AU AU2018286571A patent/AU2018286571B2/en active Active
-
2019
- 2019-06-18 CY CY20191100622T patent/CY1121698T1/el unknown
- 2019-06-19 HR HRP20191122TT patent/HRP20191122T1/hr unknown
-
2020
- 2020-05-11 AU AU2020203081A patent/AU2020203081B2/en active Active
-
2021
- 2021-06-30 HR HRP20211035TT patent/HRP20211035T1/hr unknown
- 2021-08-10 CY CY20211100720T patent/CY1124546T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528479A5 (enExample) | ||
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| JP2018505192A5 (enExample) | ||
| JP2019031514A5 (enExample) | ||
| IL256360A (en) | Dry powders of a single metal cation for inhalation | |
| JP2013536845A5 (enExample) | ||
| JP2016534153A5 (enExample) | ||
| JP2012505222A5 (enExample) | ||
| HRP20240288T1 (hr) | Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat | |
| JP2012503668A5 (enExample) | ||
| JP2013540123A5 (enExample) | ||
| JP2019517541A5 (enExample) | ||
| JP2009519935A5 (enExample) | ||
| JPWO2020074894A5 (enExample) | ||
| NZ767295B2 (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| NZ729796B2 (en) | Liquid inhalation formulation comprising rpl554 | |
| JPWO2021171034A5 (enExample) | ||
| NZ767296B2 (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| RU2013148786A (ru) | Улучшенный состав суспензии кортикостероида для ингаляционного введения | |
| WO2022007743A1 (zh) | 粘膜给药剂型和其应用 | |
| RU2021109697A (ru) | Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции | |
| JP2025502065A (ja) | ブデソニドと５－アミノ－２、３－ジヒドロ－１、４－フタラジンジオンの組合せ | |
| Seys et al. | Increased Expression of the MERS Coronavirus Receptor DPP4 in Lungs of Smokers and Patients with COPD | |
| RU2022103508A (ru) | Фармацевтическая композиция, содержащая энсифентрин | |
| NZ748596B2 (en) | Microparticles comprising a sulphur-containing compound |